骨髓增殖性疾病JAK2 V617F研究进展  

Advance of Study on JAK2 V617F in Myeloproliferative Disorders——Review

作　　者：徐媛媛[1,2] 李惠民[1] 

机构地区：[1]昆明医学院第四附属医院血液科,昆明650021 [2]解放军总医院血液科

出　　处：《中国实验血液学杂志》2009年第1期238-242,共5页Journal of Experimental Hematology

摘　　要：骨髓增殖性疾病(myeloproliferative disorders,MPD)中已明确bcr-abl是慢性粒细胞白血病发病的关键环节,但bcr-abl阴性MPD发病的分子机制研究进展缓慢。近年来多宗实验研究报道该类MPD疾病有高频获得性JAK2V617F点突变,并通过小鼠骨髓移植实验证实了该突变确实可引起真性红细胞增多症(PV)的发生,提示JAK2V617F点突变在MPD的发病机制中起重要作用。本文就JAK2及JAK2V617F点突变及其检测方法,JAK2V617点突变与MPD的发病关系,临床相关性及与其他恶性血液病的关系进行综述。The key molecular events in the pathogenesis of myeloproliferative disorders （MPD） have been poorly defined to date, except the case of chronic myeloid leukaemia with the associated rearranged gene bcr/ab1. In recent years, a number of different studies described the detection of JAK2 V617F mutation in haematopoietic cells from polycythemia vera patients and other MPDs, which indicates that it plays an important role in the pathogenesis of MPDs. In this review, the JAK2 V617F point mutation and its detection methods, its clinical correlations with MPDs and other malignant hematopathies were summarized.

关 键 词：骨髓增殖性疾病 JAK2 V617F bcr-ab1 

分 类 号：R551.3[医药卫生—血液循环系统疾病]